Andorra vs Russia: Death rate from cancer
Andorra
211.67 deaths per 100,000 people
in 2021
Russia
211.71 deaths per 100,000 people
in 2021
Andorra rank
39th
Russia rank
38th
Death rate from cancer over time
- Andorra
- Russia
How they compare
Russia currently reports 211.71 deaths per 100,000 people against 211.67 deaths per 100,000 people in Andorra, a difference of 0.04 deaths per 100,000 people.
The two have swapped places 3 times across 22 shared years of data; in 2000 it was Andorra ahead.
Andorra ranks 39th and Russia ranks 38th of 194 countries.
Andorra has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Andorra | Russia | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 213.48 deaths per 100,000 people | 201.8 deaths per 100,000 people | 11.68 deaths per 100,000 people | Andorra |
| 2010s | 216.51 deaths per 100,000 people | 203.38 deaths per 100,000 people | 13.14 deaths per 100,000 people | Andorra |
| 2020s | 233.24 deaths per 100,000 people | 212.35 deaths per 100,000 people | 20.88 deaths per 100,000 people | Andorra |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Andorra or Russia?
- Russia, at 211.71 deaths per 100,000 people against 211.67 deaths per 100,000 people in Andorra as of 2021.
- What is the difference in death rate from cancer between Andorra and Russia?
- 0.04 deaths per 100,000 people, with Russia ahead.
- How many years of comparable data are there for Andorra and Russia?
- 22 years are reported by both, from 2000 to 2021.
- How do Andorra and Russia rank globally for death rate from cancer?
- Andorra ranks 39th and Russia ranks 38th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.